The Adult Immunization Board (AIB): A new platform to provide multidisciplinary guidelines for the implementation and optimization of adult immunization in Europe
Vaccine. 2023 Dec 2:S0264-410X(23)01427-5. doi: 10.1016/j.vaccine.2023.11.060. Online ahead of print.NO ABSTRACTPMID:38044243 | DOI:10.1016/j.vaccine.2023.11.060 (Source: Vaccine)
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Jade Pattyn Marco Del Riccio Angela Bechini Greet Hendrickx Sara Boccalini Pierre Van Damme Paolo Bonanni Source Type: research
Immune thrombocytopenic purpura and Guillain-Barr é syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study
CONCLUSION: The VENUS study can provide valuable insights to facilitate the establishment of an advanced vaccine monitoring system in Japan.PMID:38044244 | DOI:10.1016/j.vaccine.2023.11.053 (Source: Vaccine)
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Shuntaro Sato Tomohiro Katsuta Yurika Kawazoe Masaki Takahashi Fumiko Murata Megumi Maeda Haruhisa Fukuda Satoshi Kamidani Source Type: research
School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec
CONCLUSION: School-based vaccination programs offer equitable access to vaccination, and our analysis showed that some groups have consistently lower vaccine acceptance and uptake. Strategies to improve HPV vaccine coverage should target children living in areas with a higher proportion of immigrants, non-French speakers, and people from underprivileged backgrounds. Although it is too early to assess the full impact of COVID-19 on school-based programs in Quebec, it remains important to ensure that catch-up strategies are implemented for missed doses.PMID:38044245 | DOI:10.1016/j.vaccine.2023.11.055 (Source: Vaccine)
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Maude Dionne Chantal Sauvageau Marilou Kiely Mourad Dahhou Denis Hamel Mika Rathwell Thilina Bandara Cory Neudorf Ève Dubé Source Type: research
Mycobacterium bovis BCG expressing the proteins CP40 or CP09720 of Corynebacterium pseudotuberculosis promotes protection in mice after challenge
In this study, we assessed the survival and immune response of mice vaccinated with recombinant Mycobacterium bovis BCG Pasteur that expressed the CP40 or CP09720 proteins after the mice were challenged with a C. pseudotuberculosis MIC-6 virulent strain. Six groups of mice (n = 10 mice per group) were immunised with a sterile 0.9% saline solution (G1), 106 CFU of M. bovis BCG Pasteur (G2), 106 CFU of M. bovis BCG/cp40 (G3), 106 CFU of M. bovis BCG/cp09720 (G4), M. bovis BCG/cp40 boosted with rCP40 (G5), and M. bovis BCG/cp09720 boosted with rCP09720 (G6). The highest survival rate of 90% was observed in the G5 group, follo...
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Rodrigo Barros de Pinho Tallyson Nogueira Barbosa Laura Dall'Agno B árbara da Rocha Fonseca Francisco Silvestre Brilhante Bezerra Fernanda Severo Sabedra Sousa Fabiana Kommling Seixas Tiago Collares Sibele Borsuk Source Type: research
The Adult Immunization Board (AIB): A new platform to provide multidisciplinary guidelines for the implementation and optimization of adult immunization in Europe
Vaccine. 2023 Dec 2:S0264-410X(23)01427-5. doi: 10.1016/j.vaccine.2023.11.060. Online ahead of print.NO ABSTRACTPMID:38044243 | DOI:10.1016/j.vaccine.2023.11.060 (Source: Vaccine)
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Jade Pattyn Marco Del Riccio Angela Bechini Greet Hendrickx Sara Boccalini Pierre Van Damme Paolo Bonanni Source Type: research
Immune thrombocytopenic purpura and Guillain-Barr é syndrome after 23-valent pneumococcal polysaccharide vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study
CONCLUSION: The VENUS study can provide valuable insights to facilitate the establishment of an advanced vaccine monitoring system in Japan.PMID:38044244 | DOI:10.1016/j.vaccine.2023.11.053 (Source: Vaccine)
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Shuntaro Sato Tomohiro Katsuta Yurika Kawazoe Masaki Takahashi Fumiko Murata Megumi Maeda Haruhisa Fukuda Satoshi Kamidani Source Type: research
School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec
CONCLUSION: School-based vaccination programs offer equitable access to vaccination, and our analysis showed that some groups have consistently lower vaccine acceptance and uptake. Strategies to improve HPV vaccine coverage should target children living in areas with a higher proportion of immigrants, non-French speakers, and people from underprivileged backgrounds. Although it is too early to assess the full impact of COVID-19 on school-based programs in Quebec, it remains important to ensure that catch-up strategies are implemented for missed doses.PMID:38044245 | DOI:10.1016/j.vaccine.2023.11.055 (Source: Vaccine)
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Maude Dionne Chantal Sauvageau Marilou Kiely Mourad Dahhou Denis Hamel Mika Rathwell Thilina Bandara Cory Neudorf Ève Dubé Source Type: research
Mycobacterium bovis BCG expressing the proteins CP40 or CP09720 of Corynebacterium pseudotuberculosis promotes protection in mice after challenge
In this study, we assessed the survival and immune response of mice vaccinated with recombinant Mycobacterium bovis BCG Pasteur that expressed the CP40 or CP09720 proteins after the mice were challenged with a C. pseudotuberculosis MIC-6 virulent strain. Six groups of mice (n = 10 mice per group) were immunised with a sterile 0.9% saline solution (G1), 106 CFU of M. bovis BCG Pasteur (G2), 106 CFU of M. bovis BCG/cp40 (G3), 106 CFU of M. bovis BCG/cp09720 (G4), M. bovis BCG/cp40 boosted with rCP40 (G5), and M. bovis BCG/cp09720 boosted with rCP09720 (G6). The highest survival rate of 90% was observed in the G5 group, follo...
Source: Vaccine - December 3, 2023 Category: Allergy & Immunology Authors: Rodrigo Barros de Pinho Tallyson Nogueira Barbosa Laura Dall'Agno B árbara da Rocha Fonseca Francisco Silvestre Brilhante Bezerra Fernanda Severo Sabedra Sousa Fabiana Kommling Seixas Tiago Collares Sibele Borsuk Source Type: research
Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries
We report on the RAVIN approach, describe how the project responded collectively to an evolving RVV product landscape, synthesize common characteristics of the RAVIN country experiences, highlight key lessons learned, and outline the unfinished agenda to inform future new vaccine introduction efforts by countries and global partners.PMID:38042696 | DOI:10.1016/j.vaccine.2023.11.035 (Source: Vaccine)
Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Mary Carol Jennings Molly Sauer Chloe Manchester Heidi M Soeters Lora Shimp Terri B Hyde Umesh Parashar Craig Burgess Brian Castro Iqbal Hossein Michel Othepa Daniel C Payne Jacqueline E Tate Jenny Walldorf Lois Privor-Dumm Vanessa Richart Mathuram Santos Source Type: research
Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023.11.048. Online ahead of print.ABSTRACTThe virus-like particle (VLP) platform is a robust inducer of humoral and cellular immune responses; hence, it has been used in vaccine development for several infectious diseases. In the current work, VLPs carrying SARS-CoV-2 Spike (S) protein (Wuhan strain) with an HIV-1 Gag core were produced using suspension HEK 293SF-3F6 cells by transient transfection. The Gag was fused with green fluorescent protein (GFP) for rapid quantification of the VLPs. Five different versions of Gag-Spike VLPs (Gag-S-VLPs) consisting o...
Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Anahita Bakhshizadeh Gashti Gerard Agbayani Sabahudin Hrapovic Nasha Nassoury Nathalie Coulombe Renu Dudani Blair A Harrison Bassel Akache R énald Gilbert Parminder Singh Chahal Source Type: research
Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial
CONCLUSIONS: Tri Fluvac was well tolerated, and immunogenicity was non-inferior to the active comparator, meeting U.S. Food and Drug Administration (FDA) criteria for adult vaccine licensure. Few acute respiratory infections were reported during intense COVID-19 pandemic restrictions, resulting in insufficient power to evaluate clinical efficacy.PMID:38042698 | DOI:10.1016/j.vaccine.2023.11.050 (Source: Vaccine)
Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Kriengkrai Prasert Prabda Praphasiri Hatairat Lerdsamran Sutthichai Nakphook Darunee Ditsungnoen Sutthinan Chawalchitiporn Kanlaya Sornwong Kittisak Poopipatpol Ponthip Wirachwong Piengthong Narakorn Somchaiya Surichan Nava Suthepakul Napawan Thangsupanim Source Type: research
Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries
We report on the RAVIN approach, describe how the project responded collectively to an evolving RVV product landscape, synthesize common characteristics of the RAVIN country experiences, highlight key lessons learned, and outline the unfinished agenda to inform future new vaccine introduction efforts by countries and global partners.PMID:38042696 | DOI:10.1016/j.vaccine.2023.11.035 (Source: Vaccine)
Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Mary Carol Jennings Molly Sauer Chloe Manchester Heidi M Soeters Lora Shimp Terri B Hyde Umesh Parashar Craig Burgess Brian Castro Iqbal Hossein Michel Othepa Daniel C Payne Jacqueline E Tate Jenny Walldorf Lois Privor-Dumm Vanessa Richart Mathuram Santos Source Type: research
Production, purification and immunogenicity of Gag virus-like particles carrying SARS-CoV-2 components
Vaccine. 2023 Dec 1:S0264-410X(23)01394-4. doi: 10.1016/j.vaccine.2023.11.048. Online ahead of print.ABSTRACTThe virus-like particle (VLP) platform is a robust inducer of humoral and cellular immune responses; hence, it has been used in vaccine development for several infectious diseases. In the current work, VLPs carrying SARS-CoV-2 Spike (S) protein (Wuhan strain) with an HIV-1 Gag core were produced using suspension HEK 293SF-3F6 cells by transient transfection. The Gag was fused with green fluorescent protein (GFP) for rapid quantification of the VLPs. Five different versions of Gag-Spike VLPs (Gag-S-VLPs) consisting o...
Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Anahita Bakhshizadeh Gashti Gerard Agbayani Sabahudin Hrapovic Nasha Nassoury Nathalie Coulombe Renu Dudani Blair A Harrison Bassel Akache R énald Gilbert Parminder Singh Chahal Source Type: research
Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial
CONCLUSIONS: Tri Fluvac was well tolerated, and immunogenicity was non-inferior to the active comparator, meeting U.S. Food and Drug Administration (FDA) criteria for adult vaccine licensure. Few acute respiratory infections were reported during intense COVID-19 pandemic restrictions, resulting in insufficient power to evaluate clinical efficacy.PMID:38042698 | DOI:10.1016/j.vaccine.2023.11.050 (Source: Vaccine)
Source: Vaccine - December 2, 2023 Category: Allergy & Immunology Authors: Kriengkrai Prasert Prabda Praphasiri Hatairat Lerdsamran Sutthichai Nakphook Darunee Ditsungnoen Sutthinan Chawalchitiporn Kanlaya Sornwong Kittisak Poopipatpol Ponthip Wirachwong Piengthong Narakorn Somchaiya Surichan Nava Suthepakul Napawan Thangsupanim Source Type: research
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshops
This article provides a brief summary of the presentations and discussions at each workshop in order to share these sessions with the broader enteric vaccine field.PMID:38036392 | DOI:10.1016/j.vaccine.2023.11.045 (Source: Vaccine)
Source: Vaccine - November 30, 2023 Category: Allergy & Immunology Authors: Shahida Baqar Aurelio Bonavia A Louis Bourgeois Joseph J Campo Allison Clifford Kurt Hanevik Mateusz Hasso-Agopsowicz William Hausdorff Robert Kaminski Calman A MacLennan Nicholas Mantis Laura B Martin Richard Omore Marcela Pasetti Patricia Pavlinac Armel Source Type: research
